Pfizer has urged a Florida federal judge to dismiss lawsuits claiming its birth control shot Depo-Provera can cause users to ...

Pfizer stock is undervalued with strong non-COVID growth, robust Q2 2025 results, and strategic R&D pivots. See more on PFE ...

Pfizer's diversified pipeline and new product launches are driving operational growth. Click here to read more about PFE ...

In Q2 2025, Pfizer reported notable revenues from key oncology drugs: The increasing demand for drugs like Padcev and the introduction of new therapies such as Elrexfio, which generated $85 million in ...

Despite the positive outlook, Pfizer still faces substantive execution risks. The looming challenge of losing exclusivity on certain drugs could impact revenue streams significantly. Moreover, while ...

The Washington State Employment Security Department has said that 100 workers are affected by Pfizer’s (NYSE:PFE) layoff, ...

One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...